It’s as if sudden cardiac arrest is met with a resigned shrug: If it’s nearly impossible to predict and even harder to treat, ...

KING OF PRUSSIA, PA — XyloCor Therapeutics has dosed the first patient in its Phase 2b EXACT-2 trial evaluating XC001 (encoberminogene rezmadenovec), a novel gene therapy designed to help patients ...